Skip to Content

Zoetis Inc Class A - Stock Quote ZTS

Rating as of

Morningstar's Zoetis Inc Class A Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Zoetis Sees Companion Animal Strength in Q1 Despite Pressure in Livestock Segment; FVE Unchanged

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Zoetis reported first-quarter results that were muted by strengthening foreign-currency headwinds, but it remains on track to meet our full-year expectations, and we’re holding steady on our fair value estimate. Coming off last year’s exceptionally strong performance, we anticipate moderation this year that will leave top- and bottom-line growth closer to prepandemic rates. We remain confident in the company’s wide economic moat, which rests on cost advantage and intangible assets. We think the latter is where the action is right now, and we're impressed by the early European commercial uptake of monoclonal antibody Librela for arthritis in dogs. Zoetis’ push into mAbs for companion animals puts the firm significantly ahead of competitors and offers a strong product to address a large and undertreated market.

Read Full Analysis

Zoetis Inc Class A's Company Profile

Business Description

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

10 Sylvan Way
Parsippany, NJ, 07054
T +1 973 822-7000
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Classic Growth
Employees 12,100

Zoetis Inc Class A's Related News